Periscope Capital’s Liminatus Pharma Warrants LIMNW Stock Holding History

Periscope Capital’s Portfolio LIMNW Stock Details LIMNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.98K	Sell	30,000 -17,500	-37%	-$1.21K	﹤0.01%	473
2026 Q1	$1.9K	Hold	47,500	–	–	﹤0.01%	423
2025 Q4	$1.73K	Hold	47,500	–	–	﹤0.01%	344
2025 Q3	$7.03K	Sell	47,500 -2,500	-5%	-$488	﹤0.01%	275
2025 Q2	$12K	Buy	+50,000	New	+$9.82K	﹤0.01%	210

Other funds holding LIMNW

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Periscope Capital's LIMNW Position: Q2 2026 in Review

Periscope Capital reduced its Liminatus Pharma Warrants (LIMNW) stake by 37% in Q2 2026, selling an estimated $1.21K and leaving 30,000 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #473.

Periscope Capital first reported a position in LIMNW in Q2 2025 and has held it in 5 quarters since. The position peaked at $12K in Q2 2025. 22 funds tracked by Wall St. Rank hold LIMNW as of Q2 2026.

Periscope Capital held 30,000 shares of Liminatus Pharma Warrants worth $1.98K as of Q2 2026.
Periscope Capital sold 17,500 Liminatus Pharma Warrants shares in Q2 2026, an estimated $1.21K.
Liminatus Pharma Warrants made up ﹤0.01% of Periscope Capital's portfolio in Q2 2026, its #473 holding.
Periscope Capital first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 5 quarters since.
Periscope Capital's Liminatus Pharma Warrants position peaked at $12K in Q2 2025.
22 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q2 2026.

Based on Periscope Capital's 13F filing for Q2 2026, filed 11 Aug 2026.